Acute Pain Pipeline Insight 2025: 25+ Innovators Advancing Non-Opioid and Multimodal Analgesics for Safer, Faster Relief | DelveInsight

DelveInsight's "Acute Pain - Pipeline Insight, 2025" provides a comprehensive overview of the dynamic and rapidly evolving pipeline targeting acute pain-a condition that affects millions annually in surgical, trauma, and emergency care settings. Despite its high prevalence, the treatment landscape remains dominated by opioids, which are associated with addiction, tolerance, and side effects. In response, biopharmaceutical companies are actively pursuing safer, more effective non-opioid alternatives and novel analgesic mechanisms.

As of 2025, more than 25 companies are engaged in clinical and preclinical development of acute pain therapies focused on improving onset time, efficacy, and safety. Leading candidates include VX-548 (Vertex Pharmaceuticals), a selective NaV1.8 inhibitor that has shown significant pain reduction without the abuse potential of opioids. Other promising agents such as HTX-011 (Heron Therapeutics), JNJ-63955918 (Johnson & Johnson), and Olinvyk (Trevena) are targeting local anesthetic pathways, G-protein-biased mu-opioid receptors, and dual-mechanism drugs to offer prolonged relief with minimal systemic exposure.

In addition to small molecules, innovative drug-device combinations, nerve blocks, and extended-release formulations are gaining traction in post-operative and emergency care pain management. Clinical trials are increasingly focusing on multimodal analgesia strategies-combining anti-inflammatory agents, local anesthetics, and neuromodulators to reduce reliance on opioids. Regulatory agencies are supporting this shift with fast-track and breakthrough therapy designations for non-addictive pain therapies, as the opioid epidemic remains a major healthcare priority.

With advancements in pain biomarker research and improved trial endpoints, the acute pain pipeline in 2025 is set to deliver new therapeutic options that not only manage pain effectively but also reduce societal and individual risks tied to opioid use. This marks a pivotal shift toward a safer, more sustainable future in pain medicine.

Interested in learning more about the current treatment landscape and the key drivers shaping the acute pain pipeline? Click here: https://www.delveinsight.com/report-store/acute-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Acute Pain Pipeline Report
• DelveInsight's acute pain pipeline analysis depicts a strong space with 25+ active players working to develop 25+ pipeline drugs for acute pain treatment.
• The leading acute pain companies include Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, Scilex Pharmaceuticals, Inc., and others are evaluating their lead assets to improve the acute pain treatment landscape.
• Key acute pain pipeline therapies in various stages of development include NTM-001, CGT 1507, TRPA1 Antagonist, TRM-362, CL-108, CLP-417, VX-548, KUR 101, VX-708, HR 18042, ST-2427, MR 107A 02, PPP001, SP-103, and others.
• In March 2025, Latigo Biotherapeutics announced that the U.S. FDA has granted Fast Track designation (FTD) to LTG-001, its oral, investigational selective Nav1.8 inhibitor for acute pain treatment.
• In February 2025, the FDA approved suzetrigine, a non-opioid prescription pill sold under the brand name JournavxTM, for treating moderate-to-severe acute pain in adults.
• In January 2025, Vertex Pharmaceuticals announced that the U.S. FDA approved JOURNAVXTM (suzetrigine), an oral, non-opioid NaV1.8 pain signal inhibitor, for treating adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medication with no evidence of addictive potential, suitable for various types of moderate-to-severe acute pain.

Request a sample and discover the recent breakthroughs happening in the acute pain pipeline landscape at https://www.delveinsight.com/report-store/acute-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Pain Overview
Acute pain is a sudden onset of pain that typically lasts for a short duration, often occurring in response to injury, illness, or surgery. It serves as a protective mechanism, alerting the body to potential harm or damage. Acute pain is usually localized and can be caused by physical trauma, burns, infections, or inflammation. The pain intensity can vary, ranging from mild discomfort to severe, sharp, or throbbing sensations.

Unlike chronic pain, which persists for months or years, acute pain generally resolves as the underlying cause is treated or heals. Management of acute pain includes analgesics, anti-inflammatory medications, and other supportive therapies, depending on the severity and origin of the pain. Proper pain management is important not only for patient comfort but also to prevent complications such as impaired healing or the development of chronic pain.

Find out more about acute pain medication at https://www.delveinsight.com/report-store/acute-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Pain Treatment Analysis: Drug Profile
NTM-001: Neumentum
NTM-001 is Neumentum's lead therapeutic candidate, featuring a novel, alcohol-free formulation of the potent NSAID ke%0rolac. This pre-mixed infusion bag is designed for 24-hour continuous administration following surgery. It is currently being evaluated for managing moderately severe acute pain that typically requires opioid-level analgesia, particularly in postoperative settings.

CGT 1507: CGeneTech
Otenaproxesul is a groundbreaking nonsteroidal anti-inflammatory drug (NSAID) that uniquely releases hydrogen sulfide. Developed by Antibe, it leverages its remarkable potency, gastrointestinal protection, and overall safety profile to address acute pain conditions. Otenaproxesul is being explored as a non-opioid alternative for post-surgical pain management.

Learn more about the novel and emerging acute pain pipeline therapies at https://www.delveinsight.com/report-store/acute-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Pain Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Acute Pain Pipeline Report
• Coverage: Global
• Key Acute Pain Companies: Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, Scilex Pharmaceuticals, Inc., and others.
• Key Acute Pain Pipeline Therapies: NTM-001, CGT 1507, TRPA1 Antagonist, TRM-362, CL-108, CLP-417, VX-548, KUR 101, VX-708, HR 18042, ST-2427, MR 107A 02, PPP001, SP-103, and others.

To dive deep into rich insights for drugs used for acute pain treatment, visit: https://www.delveinsight.com/report-store/acute-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Acute Pain Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Acute Pain Pipeline Therapeutics
6. Acute Pain Pipeline: Late-Stage Products (Phase III)
7. Acute Pain Pipeline: Mid-Stage Products (Phase II)
8. Acute Pain Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.